COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study
Authors:
- Jadwiga Węcławek-TompolJWJadwiga Węcławek-Tompol
- Zuzanna ZakrzewskaZZZuzanna Zakrzewska
- Olga Gryniewicz-KwiatkowskaOGOlga Gryniewicz-Kwiatkowska
- Filip PierlejewskiFPFilip Pierlejewski
- Ewa BieńEBEwa Bień
- Agnieszka Zaucha-PrażmoAZAgnieszka Zaucha-Prażmo
- Olga Zając-SpychałaOZOlga Zając-Spychała
- Anna Szmydki-BaranASAnna Szmydki-Baran
- Agnieszka Mizia-MalarzAMAgnieszka Mizia-Malarz
- Małgorzata Sawicka-ŻukowskaMSMałgorzata Sawicka-Żukowska
- Agnieszka KrukAKAgnieszka Kruk
Open Access
- 11 October 2021
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-10
Abstract
Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, children present milder symptoms, with most having an asymptomatic course. We hypothesized that COVID-19 infection has a negative impact on the continuation of chemotherapy and increases nonrelapse mortality. Material and methods: This study was performed to assess the course of SARS-CoV-2 among children with hematological or oncological malignancies and its impact on cancer therapy. Records of SARS-CoV-2 infection in 155 children with malignancies from 14 Polish centers for pediatric hematology and oncology were collected and analyzed. Results: SARS-CoV-2 replication was observed in 155 patients. Forty-nine patients were symptomatic, with the following being the most common manifestations: fever (31 patients), gastrointestinal symptoms (10), coryza (13), cough (13) and headache (8). In children who were retested, the median time of a positive PCR result was 16 days (range 1–70 days), but 12.7% of patients were positive beyond day + 20. The length of viral PCR positivity correlated with the absolute neutrophil count at diagnosis. Seventy-six patients did not undergo further SARS-CoV-2 testing and were considered convalescents after completion of isolation. Antibiotic therapy was administered in 15 children, remdesivir in 6, convalescent plasma in 4, oxygen therapy in 3 (1—mechanical ventilation), steroids in 2, intravenous immunoglobulins in 2, and heparin in 4. Eighty patients were treated with chemotherapy within 30 days after SARS-CoV-2 infection diagnosis or were diagnosed with SARS-CoV-2 infection during 30 days of chemotherapy administration. Respiratory symptoms associated with COVID-19 and associated with oxygen therapy were present in 4 patients in the study population, and four deaths were recorded (2 due to COVID-19 and 2 due to progressive malignancy). The probability of 100-day overall survival was 97.3% (95% CI 92.9–99%). Delay in the next chemotherapy cycle occurred in 91 of 156 cases, with a median of 14 days (range 2–105 days). Conclusions: For the majority of pediatric cancer patients, SARS-CoV-2 infection does not result in a severe, life-threatening course. Our data show that interruptions in therapy are common and can result in suboptimal therapy.Keywords
Funding Information
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (SUB.C200.21.058, SUB.C200.21.058)
This publication has 31 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatmentEuropean Journal of Cancer, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- Early advice on managing children with cancer during the COVID‐19 pandemic and a call for sharing experiencesPediatric Blood & Cancer, 2020
- Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 PneumoniaThe Journal of Infectious Diseases, 2020
- Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)medRxiv, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility studyThe Lancet Oncology, 2013
- Chemotherapy dose-intensity and survival for childhood medulloblastoma.2012